Solubility and Dissolution Study by Applying the Fusion Method of Solid Dispersion, the Hydrophobic Drugs Glimepiride Solubility is Improved

Glimepiride is a member of the third generation of sulfonylureas used to treat diabetes mellitus. Even though glimepiride has moderate water solubility, its slow rate of dissolution means that it only completely dissolves in the intestines, resulting in subtherapeutic plasma drug levels and, occasionally, an unanticipated clinical reaction. The goal of this research was to enhance the drug's solubility, rate of dissolution, and biological performance. The best glimepiride solid dispersion (SDs) formulation was then employed to create SDs tablets by blending the medication with the water-soluble polymers HPMC, PEG 4000, and GUM KARAYA. The formulations for the capsules were made using the capsule filling process. In addition to FTIR, XRD, and SEM examinations of SDs, there were in vitro dissolving tests. For SDs made with the fusion process, the best dissolving profile was 1:5 ratio of drug to HPMC, PEG 4000, and GUM KARAYA polymer. For capsule formulations, the best dissolving profile was 1:2 ratio of HPMC. Results showed that the promising polymer, HPMC, enhanced glimepiride's solubility. The capsules were produced and then processed according to standard pharmacopeial guidelines. Scientists found no evidence of drug-polymer interaction in stability or FT-IR studies.